Cancerguard screens for 50 types of cancer with one blood test. Doctors explain the accuracy, benefits and limits of multi-cancer early detection tests.

Exact Sciences Corporation EXAS has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States.

Nearly 70 percent of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening.1,2,3 The Cancerguard test can help address the unmet need by complementing existing ...

Exact Science’s Michelle Beidelschies, PhD, reveals how a multi-biomarker class multi-cancer early detection test (MCED) blood test can help health systems expand detection across more cancers earlier ...

Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical ...

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

The FDA could approve the first blood test that can detect multiple cancers, around the end of the year, setting the stage ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...